Connect with us

BUSINESS

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Speaks Out On The Recent Characterization Studies

Published

on

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is pleased to announce details regarding a study it conducted recently. An official working with the company said they were compelled to undertake the study as part of the requirements by FDA on the latest investigational New Drug Application called 22P1G.

Pancreatic cancer (LAPC) is a condition that quite a significant number of people have been struggling with around the globe and the company hopes to achieve success in its clinical trial. That will be in a bid to offer lasting and effective solutions. It will be an undertaking that will involve a series of tests by experts and that is the reason the company is making prior preparations to ensure that matters run smoothly.

Benefits of Cell-in-a Box® capsules 

If all moves according to plan, the company’s Cell-in-a Box® capsules will play a significant role towards the treatment of the locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) and the cells from the MCB will be the ones serving as the active pharmaceutical ingredient (API) in the entire process. All this will be happening in the organized clinical trial and the future is looking promising.

FDA’s role

The U.S. Food and Drug Administration (FDA) will be scrutinizing the studies that are currently underway.

The Chief Executive Officer of PharmaCyte opined, “PharmaCyte is complying with all of the FDA guidelines and recommendations for all cell tests and other recent studies with the 22P1G cells. Successful completion of these studies was a pre-requisite for the approval by the FDA for us to conduct a clinical trial in patients with LAPC.”

Nature of the treatment

This company official termed the completion of the studies a pre-requisite for the approval by the FDA adding that it was the only way they would be able to carry out a clinical trial in patients with LAPC.

It is worth noting that this treatment is primarily reliant on the genetically engineered live-human cells that release a potent cytochrome P450 enzyme which helps with the activation of the chemotherapy prodrug ifosfamide (clone 22P1G cells).

PharmaCyte’s Scientific Advisory Board is currently headed by Dr. Löhr. And a person well conversant with the latest developments has disclosed that he was the one that served as the Principal Investigator of the two clinical trials. Those trials were conducted earlier using Cell-in-a-Box® technology in the large number of patients that had been suffering from advanced metastatic pancreatic cancer.

BUSINESS

Amazon.com, Inc (NASDAQ:AMZN) CEO Jeff Bezos Rich Enough To Buy Any NFL Team

Published

on

Amazon.com, Inc (NASDAQ:AMZN) has gotten to its outstanding business success levels because of the good leadership of Jeff Bezos. The company’s CEO seems to be growing at almost the same level. Reports indicate that this leader can purchase almost anything he might want in the wide world. It is common for people to pay attention whenever a man of Jeff’s stature declares interest to purchase something.

The financial standing of Bezos

Bezos is the owner of The Washington Post, and almost everyone knows how successful it has become.

This time around, all eyes focus on the leader after he expressed interest in purchasing an NFL team.

This is not a fuss considering that he has already spoken to a number of the NFL owners. One of them is Daniel Snyder, who is the big name behind the Washington Redskins.

Reports also indicate that the CEO on Thursday expressed his interest in the purchase of the Seattle Seahawks.

Analysts’ perspective

Analysts have lately been speaking about the growing interest of Bezos in owning an NFL team. They think that this is highly likely considering how rich this entrepreneur is. He is currently worth $109.5 billion, which is enough to buy off any NFL team that may interest him at any time.

The Dallas Cowboys stands out as one of the most highly valued, and it is worth $5.5 billion. This is as per the Forbes rankings that have also placed Redskins at almost $3.4 billion. The same body says that Seahawks may stand at about $2.78 billion. From these details, it is easy to tell that this man could succeed in bagging any team he might want.

The CEO is rich, and that is a matter no one can dispute. However, to strike larger deals, he might be compelled to liquidate some of his assets. These include the multi-billion dollar homes under his name, among other investments.

The official also has many shares in Amazon, and he might also have to sell those whenever he wants to buy something of significant value. Analysts say that a huge deal of his wealth has come from a large number of shares that he owns at Amazon.

Continue Reading

BUSINESS

Alphabet Inc (NASDAQ:GOOGL) Moves Into The Gaming Space With Its Stadia

Published

on

Alphabet Inc (NASDAQ:GOOGL) is proving to be one of the most dynamic companies around the globe. This is in terms of leading in innovation and the unveiling to high-quality goods and services. This time around it is about the unveiling of Stadia.

An outlook at Stadia

This is a major step into the gaming industry, and analysts say this might end up being Netflix in the gaming segment.

One of the most outstanding attributes of the new service is the freedom it poses to players. It won’t be necessary for them to have either a console or a hard copy to get in the game. This is a massive step that the company hopes to use to woo a significant number of players globally to its service.

Stadia pulls in with very strong momentum, and that is clear from a large number of games it will support. Some are even ready, and players will access them at what Google describes to be reasonable rates.

The situation in the market

The market is filled with rivals, and most of them are striving to take up leadership. This business guru knows it won’t be easy but still hopes to make it big.

Most of the rivals have been taking the perspective that the future of gaming lies in the cloud network. This is a shift in thinking where most people believed it could only function with hardware.

The competitors are busy carrying out tests on their products. For instance, Microsoft Corporation (NASDAQ:MSFT) is working on enhancing its Project xCloud service. On the other hand,

Amazon.com, Inc (NASDAQ:AMZN) is busy working on its cloud gaming service. However, this isn’t from a reliable source. Anytime soon, we may get to hear something about it.

Phil Harrison, who is the current head of Google Stadia, says that they are working on enhancing the technology. He believes that players need something quite close to reality.

Gamers will be required to pay an already set subscription bundle to play. There is the Premiere Edition at $129.99 pulling along with a Stadia controller. The others are free-pass and a Chromecast dongle. Those that subscribe will be free to let a friend play for free for about three months.

Continue Reading

BUSINESS

Surna Inc (OTCMKTS:SRNA) Sets A New Record High In Q3 2019 Revenues: Surna Signs Control Accords For $687,000

Published

on

Surna Inc (OTCMKTS:SRNA) has set a new record high in Q3 2019 revenues. It has posted revenues of $5.5 million in Q3, an increase of 66% when compared to the same quarter last year. It is on the backdrop of revenue realization of $3.9 million from two expansion contracts executed with a multi-facility operator in the last quarter.

Chief Executive Officer of Surna, Tony McDonald, said the company is excited to report record profits and revenues consecutively in the second straight quarter. It will focus on profitability and growth going forward to offer rich dividends to the shareholders.

Signs seven control contracts

Surna is pleased to announce the signing of agreements for controls, Sentry IQ sensors, and automation platforms in Q3 2019, with two multi-facility operators for $218,000. The company also entered the other two agreements worth $295,000 for controls with independent cultivators. Surna strengthens its footprint in the automation and technology advancement of the indoor growth facility by improving controls business. The company has signed a total of seven control contracts valued at $687,000 through September 2019.

Custom ducted air handling system

Surna is pleased to deliver a custom ducted air handling system in June 2019. It acts as a substitute for improved and new ductless fan coil units. The ability to deliver high capacity air handling systems expects to bring in new opportunities for the company from multi-facility operators. Surna derived revenues of $2.27 million after it signed sales contracts for ducted air handling systems through September 2019.

Identifies business verticals

Surna expects to complement its climate control business that comprises cultivation management technology, fertigation, lighting, operational improvement analytics, and benches through its already identified business verticals. The company will rope in firms aligned with its strategic direction to enter alliances in co-marketing, reseller, distribution, and product development.

Strategic agreements may become acquisition targets in the future. Surna expects to maintain operating profitability (cash) consistently through the infusion of growth equity, acquisitions, and execution of the growth plan. It plans to get listed on NASDAQ in 2021.

Introduces purpose-built fan coil products

Surna introduced a complete purpose-built fan coil product line in August 2019. They find usage in ductless and ducted operations for large to small indoor cannabis facilities for commercial use.

Continue Reading



Trending Stories